Seeking Expanded Indications for Biliary Tract Cancer, Breast Cancer, and More

Celltrion announced on June 12 that it has demonstrated the superior efficacy and tolerability of its next-generation multi-antibody drug candidate, CT-P72/ABP-102, and confirmed its potential for expanding indications to various solid tumors.


Celltrion Confirms Tolerability and Anti-Tumor Efficacy of Multi-Antibody Drug... Plans US Fast Track Application This Year View original image

On June 11, at the “World Bispecific Antibody & T-Cell Engager Summit South Korea” held in Seoul, Celltrion presented these findings under the theme of HER2 TCE CT-P72/ABP-102, which boasts an excellent therapeutic index (TI).


According to the presentation, in vitro cytotoxicity assays showed that CT-P72/ABP-102 exhibited strong anti-tumor activity against HER2-overexpressing tumors, while its cytotoxicity against HER2-low-expressing cells was significantly reduced, indicating high selectivity for cancer cells. In pharmacokinetic (PK) and toxicity studies using non-human primates, the drug demonstrated excellent tolerability at doses up to 80 mg/kg.


In a gastric cancer xenograft animal model that had developed resistance to existing therapies, CT-P72/ABP-102 exhibited anti-tumor effects that surpassed those of conventional drugs. The drug also demonstrated strong anti-tumor efficacy in HER2-overexpressing bladder cancer, biliary tract cancer, and breast cancer, suggesting the potential for expanding its indications to a variety of cancers.


For breast cancer, powerful anti-tumor effects such as T-cell infiltration were also confirmed using microphysiological systems (MPS) based on organoids. MPS are tools that examine drug responses in artificially constructed environments that closely mimic those of actual patients. Through this approach, Celltrion further enhanced the predictive reliability of drug efficacy, independently of traditional animal testing, prior to patient administration.


Based on these research results, Celltrion plans to accelerate the clinical development of CT-P72/ABP-102, aiming to overcome the resistance and tolerability limitations of existing HER2-overexpressing cancer treatments (such as ENHERTU, with the active ingredient trastuzumab deruxtecan) and address unmet medical needs as a best-in-class new drug.


CT-P72/ABP-102 is an immuno-oncology drug currently being jointly developed by Celltrion and the U.S.-based biotech Abpro Holdings. It is a T-cell engager (TCE) therapy that links HER2-expressing cancer cells with T cells. In December of last year, it received U.S. Food and Drug Administration (FDA) approval for Phase 1 clinical trials and is currently in the patient screening stage. Celltrion also plans to apply for FDA Fast Track designation within this year.


Celltrion is actively advancing patient dosing for three antibody-drug conjugate (ADC)-based anti-cancer drug candidates (CT-P70, CT-P71, and CT-P73) that have entered Phase 1 clinical trials. This drug development portfolio also drew significant attention at the “Celltrion Science & Innovation Day 2026,” held last month for domestic and international analysts and institutional investors.



A Celltrion official stated, “Through preclinical studies, the multi-antibody anti-cancer drug CT-P72/ABP-102 has demonstrated high anti-tumor efficacy and excellent tolerability targeting HER2-overexpressing cancers. In addition, since it has shown therapeutic potential for various solid tumors, we will continue to do our best to successfully progress through clinical trials and develop a best-in-class new drug that surpasses existing therapies.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing